4.7 Article

Lentivirus-mediated RNA interference against Japanese encephalitis virus infection in vitro and in vivo

Journal

ANTIVIRAL RESEARCH
Volume 108, Issue -, Pages 56-64

Publisher

ELSEVIER
DOI: 10.1016/j.antiviral.2014.05.008

Keywords

JEV; Lentiviral shRNA; Antiviral; Inflammatory response; In vitro and in vivo

Funding

  1. National Special Research Programs for Non-Profit Trades, Ministry of Agriculture [200803015, 201203082]
  2. National Special Research Programs for Cultivating New Transgenic Organisms, Ministry of Agriculture [2009ZX08006-007B]

Ask authors/readers for more resources

Japanese encephalitis virus, a serious mosquito-borne flavivirus, causes acute encephalitis in humans and many animals, with a high fatality rate. RNA interference is a reasonable antiviral mechanism for target gene silencing. In this study, four lentiviral shRNAs (LV-E1, LV-E2, LV-NS3 and LV-NS4b) were constructed. The results showed that four recombinant lentiviruses suppressed JEV replication in vitro. Through treatment with LV-E1 or LV-E2, the TCID50 values were reduced by 10(3)-fold during 120 h post-challenge; the relative expression of viral mRNA was <7% or 13% in mouse and human neuroblastoma cells. Lentiviral shRNAs displayed robust inhibitory activity in various cells and against different genotypes of JEV. In vivo, pre-treatments of LV-E1 or LV-E2 resulted in no viral particles being observed in suckling mice brain sections. For 21 days of observation, 100% of mice were protected against lethal JEV injection by two pre-treatments with LV-E1 or LV-E2; the survival of the mice pre-challenged with lethal JEV was 88.3%/66.7% by treatment with LV-E1 or LV-E2. LV-E1 and LV-E2 suppressed the induction of inflammatory mediators effectively in neuroblastoma cells and mice. Lentiviral shRNAs significantly inhibit JEV infection for long-term in vitro and in vivo and effectively reduce the inflammatory response and relieve encephalitis symptoms, highlighting the feasibility of using lentivirus-mediated RNAi for potential therapy in JEV infection. (C) 2014 Elsevier B.V. All rights reserved.

Authors

I am an author on this paper
Click your name to claim this paper and add it to your profile.

Reviews

Primary Rating

4.7
Not enough ratings

Secondary Ratings

Novelty
-
Significance
-
Scientific rigor
-
Rate this paper

Recommended

No Data Available
No Data Available